OBJECTIVE: To estimate the prevalence, types, and sociodemographic and biobehavioral correlates of antinuclear antibodies (ANAs) in the US. METHODS: We conducted a cross-sectional analysis of 4,754 individuals from the National Health and Nutrition Examination Survey 1999-2004. ANAs were assessed by indirect immunofluorescence. In ANA-positive individuals, cellular staining patterns were determined, and specific autoantibody reactivities were assessed by immunoprecipitation. RESULTS: The ANA prevalence in the US population of individuals ages 12 years and older was 13.8% (95% confidence interval [95% CI] 12.2-15.5%). ANA prevalence increased with age (P=0.01), and ANAs were more prevalent among females than males (17.8% versus 9.6%; P<0.001), with the female-to-male ratio peaking at 40-49 years of age. ANA prevalence was modestly higher in African Americans compared with whites (age-adjusted prevalence odds ratio [POR] 1.30, 95% CI 1.00-1.70). Remarkably, ANAs were less common in overweight and obese individuals (age-adjusted POR 0.74) than in persons of normal weight. No significant associations of ANA with education, family income, alcohol use, smoking history, serum levels of cotinine, or C-reactive protein were observed. In ANA-positive individuals, nuclear patterns were seen in 84.6%, cytoplasmic patterns were seen in 21.8%, and nucleolar patterns were seen in 6.1%; the most common specific autoantibodies were anti-Ro (3.9%) and anti-Su (2.4%). CONCLUSION: These findings suggest that more than 32 million persons in the US have ANAs, and that the prevalence is higher among females, older individuals, African Americans, and those with a normal body weight. These data will serve as a useful baseline for future investigations of predictors and changes in ANA prevalence over time.
OBJECTIVE: To estimate the prevalence, types, and sociodemographic and biobehavioral correlates of antinuclear antibodies (ANAs) in the US. METHODS: We conducted a cross-sectional analysis of 4,754 individuals from the National Health and Nutrition Examination Survey 1999-2004. ANAs were assessed by indirect immunofluorescence. In ANA-positive individuals, cellular staining patterns were determined, and specific autoantibody reactivities were assessed by immunoprecipitation. RESULTS: The ANA prevalence in the US population of individuals ages 12 years and older was 13.8% (95% confidence interval [95% CI] 12.2-15.5%). ANA prevalence increased with age (P=0.01), and ANAs were more prevalent among females than males (17.8% versus 9.6%; P<0.001), with the female-to-male ratio peaking at 40-49 years of age. ANA prevalence was modestly higher in African Americans compared with whites (age-adjusted prevalence odds ratio [POR] 1.30, 95% CI 1.00-1.70). Remarkably, ANAs were less common in overweight and obese individuals (age-adjusted POR 0.74) than in persons of normal weight. No significant associations of ANA with education, family income, alcohol use, smoking history, serum levels of cotinine, or C-reactive protein were observed. In ANA-positive individuals, nuclear patterns were seen in 84.6%, cytoplasmic patterns were seen in 21.8%, and nucleolar patterns were seen in 6.1%; the most common specific autoantibodies were anti-Ro (3.9%) and anti-Su (2.4%). CONCLUSION: These findings suggest that more than 32 million persons in the US have ANAs, and that the prevalence is higher among females, older individuals, African Americans, and those with a normal body weight. These data will serve as a useful baseline for future investigations of predictors and changes in ANA prevalence over time.
Authors: G Candore; M P Grimaldi; F Listi; V Ferlazzo; G Colonna-Romano; M Motta; M Malaguarnera; G Fradá; D Lio; C Caruso Journal: Arch Gerontol Geriatr Suppl Date: 2002
Authors: Solange Assuncion Villagra Fernandez; Alice Zoghbi Coelho Lobo; Zilda Najjar Prado de Oliveira; Ligia Maria Ichimura Fukumori; Alexandre Marques P rigo; Evandro A Rivitti Journal: Rev Hosp Clin Fac Med Sao Paulo Date: 2004-01-28
Authors: R Uibo; I Talja; R Jôgi; C Janson; E Björnsson; G Boman; M Mandel; B Björkstén Journal: Int Arch Allergy Immunol Date: 1998-10 Impact factor: 2.749
Authors: M Satoh; J J Langdon; C H Chou; D P McCauliffe; E L Treadwell; T Ogasawara; M Hirakata; A Suwa; P L Cohen; R A Eisenberg Journal: Clin Immunol Immunopathol Date: 1994-10
Authors: Agnieszka Szymula; Jacob Rosenthal; Barbara M Szczerba; Harini Bagavant; Shu Man Fu; Umesh S Deshmukh Journal: Clin Immunol Date: 2014-02-19 Impact factor: 3.969
Authors: Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Federica Vanoni; Sebastiano A G Lava; Emilio F Fossali; Riccardo Cavalli; Giacomo D Simonetti; Mario G Bianchetti; Marie-Ange Bozzini; Carlo Agostoni; Gregorio P Milani Journal: Clin Rev Allergy Immunol Date: 2017-12 Impact factor: 8.667